Isofol Medical Overview

  • Founded
  • 2008

Founded
  • Status
  • Public

  • Employees
  • 14

Employees
  • Stock Symbol
  • ISOFOL

Stock Symbol
  • Investments
  • 1

  • Share Price
  • $0.78

  • (As of Thursday Closing)

Isofol Medical General Information

Description

Isofol Medical AB is a pharmaceutical company. It is a manufacturer of folate-based therapies. The company's drug candidate Modufolin enhances the effect of the current chemotherapy treatment for patients treated for colorectal cancer. Its products are used to increase efficacy and reduce the side effects of antimetabolite cancer treatment.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Other Industries
Other Healthcare Services
Hospitals/Inpatient Services
Stock Exchange
STO
Primary Office
  • Biotech Center
  • Arvid Wallgrens Backe 20
  • 413 46 Gothenburg
  • Sweden
+46 031-797 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Isofol Medical Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.78 $0.85 $0.73 - $1.60 $126M 162M 178K -$0.17

Isofol Medical Financials Summary

In Thousands,
USD
TTM 31-Mar-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 121,714 125,604 267,661 50,093
Revenue 2,402 2,609 4,026 0
EBITDA (23,116) (23,113) (20,289) (16,901)
Net Income (23,281) (23,318) (20,497) (17,084)
Total Assets 37,824 44,350 18,058 15,666
Total Debt 36 183 380 448
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Isofol Medical Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Isofol Medical‘s full profile, request access.

Request a free trial

Isofol Medical Patents

Isofol Medical Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20190212341-A1 Methods for treating colorectal and metastatic colorectal cancers Pending 03-Apr-2018 0000000000
AU-2019205861-A1 Methods for treating colorectal and metastatic colorectal cancers Pending 05-Jan-2018 00000000000
CA-3087514-A1 Methods for treating colorectal and metastatic colorectal cancers Pending 05-Jan-2018 00000000000
JP-2021510140-A How to treat colorectal cancer and metastatic colorectal cancer Pending 05-Jan-2018 00000000000
EP-3735267-A1 Methods for treating colorectal and metastatic colorectal cancers Pending 05-Jan-2018 A61K31/4745
To view Isofol Medical’s complete patent history, request access »

Isofol Medical Executive Team (10)

Name Title Board Seat Contact Info
Ulf Jungnelius Chief Executive Officer
Gustaf Albert Chief Financial Officer, Finance & Executive
Roger Tell Chief Medical Officer & Chief Scientific Officer
Jonathan Holmén Director, Business Development
Jenny Sundqvist Chief Commercial Officer
You’re viewing 5 of 10 executive team members. Get the full list »

Isofol Medical Board Members (4)

Name Representing Role Since
00000 0000000 00.0 Self Board Member 000 0000
0000 00000000000 00.0 Self Board Member 000 0000
00000 00000000 Isofol Medical Board Member 000 0000
You’re viewing 3 of 4 board members. Get the full list »

Isofol Medical Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Isofol Medical Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 01-Jan-2010 00000 0000 Drug Discovery
To view Isofol Medical’s complete investments history, request access »